Lysulin secures 5th patent for diabetes management supplement
Lysulin, Inc. recently announced they have secured patent approval for their flagship product Lysulin, a dietary supplement formulated for people with Type 2 diabetes and prediabetes.
“Although the formulation is very simple, it is covered by 5 issued patents. The main ingredients are lysine, zinc and vitamin C. All three ingredients have been individually shown to lower glucose and lysine stops protein glycation,” noted Dr. John Burd, founder & CEO of Lysulin, Inc.
The sponge effect
The company said their all-natural product provides a breakthrough approach for blood glucose management by preventing protein glycation, which is the cause of insulin resistance and type 2 diabetes.
Lysulin acts like a sponge to remove glucose from the bloodstream, soaking up the glucose before it reacts with the proteins. According to Burd, the product has been proven to inhibit protein glycation by the reaction of the lysine in Lysulin with the glucose in the blood.
“Glucose is the essential source of energy for the human body. It primarily comes from eating carbohydrates. After eating, the glucose in our bloodstream rises, signaling the pancreas to produce insulin. The job of insulin is to remove the glucose from the bloodstream and transport it into our cells where it is used for energy production. Although everyone needs a certain amount of glucose for daily energy production, it is also toxic to the body. The toxicity is due to Protein Glycation. Protein Glycation leads to insulin resistance, insulin depletion, the formation of Advanced Glycation Endproducts, Type 2 diabetes, and disease complications,” explained Burd. “Glucose is an aldehyde that reacts with the amino groups found on the amino acids of all proteins. When glucose reacts with these amino groups it forms a fructosamine bond. These glycated proteins progress through a series of reactions to become Advanced Glycation Endproducts (AGEs). AGEs are believed to be responsible for many, if not all, of the disease complications associated with diabetes such as retinopathy, nephropathy and neuropathy leading to blindness, kidney failure and amputations. If protein glycation is slowed or halted, the complications of diabetes may be reduced or stopped and the progression of prediabetes to Type 2 diabetes might also be slowed or halted.”
Science
“It is very important for Lysulin to be backed by science,” said Burd. “Historically, vitamins and supplements have a bad reputation because manufacturers have made unsubstantiated claims. Lysulin is very different because it is based upon published evidence, including clinical trials.”
Burd led a double-blind, placebo-controlled clinical study that examined 67 participants over a 12-week period. The study noted reductions in hemoglobin A1c test levels and blood pressure in people taking Lysulin as compared to people taking a placebo. Improved insulin resistance and beta cell function were also observed. The report stated that further confirmatory clinical studies are planned to verify the results observed in the study.
Market
Per the Centers for Disease Control and Prevention (CDC), over 34 million Americans have diabetes, —that’s just over 1 in 10. The Center also found that 1 in 3 (88 million) US adults are prediabetic. Overall, new diabetes cases have decreased in the US, with the exception of youth, which has significantly increased in recent years.
According to a report from Transparency Market Research, the type 2 diabetes segment is expected to gain significant share of the global diabetes supplements market by 2027.
The report attributes recent product launches, high adoption of dietary supplement use, the growing geriatric population, and increased healthy lifestyle awareness among diabetics as factors driving the North American market.
